February 1, 2021 -- Aizon has launched its Aizon Bioreactor Application, a predictive analysis and deep knowledge management application. The technology will allow pharmaceutical and biotechnology companies to leverage rich datasets generated during upstream manufacturing to detect and accurately predict deviations and outcomes.
The company is able to achieve good practice (GxP) compliance and provide an audit trail from the start of the "smart manufacturing" process. The technology can potentially lead to hundreds of millions of dollars in cost savings, reduced risk, and additional revenues.
The bioreactor application is designed to work with continuous and fed-batch bioreactors and helps companies understand their bioprocess manufacturing lifecycle. The cloud-based application uses specialized "edge artificial intelligence" and contextualization to make the data actionable. The data is analyzed and visualized through a persona-based lens for root cause analysis, real-time monitoring, and predictive insights across bioreactor units and manufacturing sites.
Companies can use the bioreactor application to further their digital transformation objectives toward pharma 4.0 and future-proof the path to continued process verification (CPV), according to Aizon. The technology is available as a single application or as a seamless solution within Aizon's Enterprise Platform.
Copyright © 2021 scienceboard.net